Johan Reutfors1, Therese M-L Andersson2, Philip Brenner3, Lena Brandt3, Allitia DiBernardo4, Gang Li4, David Hägg3, Louise Wingård3, Robert Bodén5. 1. Karolinska Institutet, Centre for Pharmacoepidemiology, Department of Medicine Solna, Karolinska University Hospital, Stockholm, Sweden. Electronic address: johan.reutfors@ki.se. 2. Karolinska Institutet, Department of Medical Epidemiology and Biostatistics, Stockholm, Sweden. 3. Karolinska Institutet, Centre for Pharmacoepidemiology, Department of Medicine Solna, Karolinska University Hospital, Stockholm, Sweden. 4. Janssen, Global Services, Titusville, NJ, USA. 5. Karolinska Institutet, Centre for Pharmacoepidemiology, Department of Medicine Solna, Karolinska University Hospital, Stockholm, Sweden; Uppsala University, Department of Neuroscience, Psychiatry, Uppsala, Sweden.
Abstract
BACKGROUND: The impact of treatment resistant depression (TRD) on mortality is not established. METHODS: Using Swedish national registers, 118,774 patients between 18-69 years of age who had been prescribed an antidepressant and been diagnosed with depression in specialized care were identified. Patients with at least two additional treatment trials during the same depressive episode were classified as having TRD. Data on the covariates of sex, age, history of depression, self-harm, substance use disorders, and other psychiatric and somatic comorbidities was also used. Relative risks comparing TRD patients with other depressed patients were calculated as hazard ratios (HR) for all-cause mortality and for external and non-external causes of death, as well as excess mortality rate ratios (EMRR), with 95% confidence intervals (CI). RESULTS: In total 15,013 patients (13%) were classified with TRD. Adjusted HR for all-cause mortality was 1.35 (95% CI 1.21-1.50). Mortality from external causes (including suicides and accidents) was markedly higher in TRD patients than in other depressed patients (HR 1.97; 1.69-2.29), while mortality from non-external causes was similar. The adjusted EMRR was 1.52 (1.31-1.76), highest among patients 18-29 years old (EMRR 2.03; 1.31-1.76) and patients without somatic comorbidity (EMRR 1.99; 1.63-2.43). LIMITATIONS: Severity of depression and adherence to treatment were not available in the data. CONCLUSIONS: Patients with TRD may have an increased all-cause mortality compared to other depressed patients, mainly for external causes of death. The relative mortality is highest among young and physically healthy patients.
BACKGROUND: The impact of treatment resistant depression (TRD) on mortality is not established. METHODS: Using Swedish national registers, 118,774 patients between 18-69 years of age who had been prescribed an antidepressant and been diagnosed with depression in specialized care were identified. Patients with at least two additional treatment trials during the same depressive episode were classified as having TRD. Data on the covariates of sex, age, history of depression, self-harm, substance use disorders, and other psychiatric and somatic comorbidities was also used. Relative risks comparing TRD patients with other depressedpatients were calculated as hazard ratios (HR) for all-cause mortality and for external and non-external causes of death, as well as excess mortality rate ratios (EMRR), with 95% confidence intervals (CI). RESULTS: In total 15,013 patients (13%) were classified with TRD. Adjusted HR for all-cause mortality was 1.35 (95% CI 1.21-1.50). Mortality from external causes (including suicides and accidents) was markedly higher in TRD patients than in other depressedpatients (HR 1.97; 1.69-2.29), while mortality from non-external causes was similar. The adjusted EMRR was 1.52 (1.31-1.76), highest among patients 18-29 years old (EMRR 2.03; 1.31-1.76) and patients without somatic comorbidity (EMRR 1.99; 1.63-2.43). LIMITATIONS: Severity of depression and adherence to treatment were not available in the data. CONCLUSIONS:Patients with TRD may have an increased all-cause mortality compared to other depressedpatients, mainly for external causes of death. The relative mortality is highest among young and physically healthy patients.
Authors: Jennifer G. Levitt; Guldamla Kalender; Joseph O’Neill; Joel P. Diaz; Ian A. Cook; Nathaniel Ginder; David Krantz; Michael J. Minzenberg; Nikita Vince-Cruz; Lydia D. Nguyen; Jeffry R. Alger; Andrew F. Leuchter Journal: J Psychiatry Neurosci Date: 2019-11-01 Impact factor: 6.186
Authors: Lucas McKeown; Rachael W Taylor; Elana Day; Rupal Shah; Lindsey Marwood; Helena Tee; Jess Kerr-Gaffney; Emanuella Oprea; John R Geddes; R Hamish McAllister-Williams; Allan H Young; Anthony J Cleare Journal: J Psychopharmacol Date: 2022-04-27 Impact factor: 4.562
Authors: Michael Fritz; Anna M Klawonn; Qingyu Zhao; Edith V Sullivan; Natalie M Zahr; Adolf Pfefferbaum Journal: J Neuroimmunol Date: 2020-08-26 Impact factor: 3.478
Authors: Sahar Derakhshanian; Maxine Zhou; Alexander Rath; Rachel Barlow; Sarah Bertrand; Caroline DeGraw; Christopher Lee; Jamal Hasoon; Alan D Kaye Journal: Health Psychol Res Date: 2021-06-22
Authors: Heidi Taipale; Johan Reutfors; Antti Tanskanen; Lena Brandt; Jari Tiihonen; Allitia DiBernardo; Ellenor Mittendorfer-Rutz; Philip Brenner Journal: BMC Psychiatry Date: 2020-05-13 Impact factor: 3.630
Authors: Philip Brenner; Lena Brandt; Gang Li; Allitia DiBernardo; Robert Bodén; Johan Reutfors Journal: Addiction Date: 2019-04-15 Impact factor: 6.526
Authors: David Hägg; Philip Brenner; Johan Reutfors; Gang Li; Allitia DiBernardo; Robert Bodén; Lena Brandt Journal: PLoS One Date: 2020-07-30 Impact factor: 3.240